Sign in

    Yennen

    Director and Equity Research Analyst at Wells Fargo

    Chris Yennen is a Director and Equity Research Analyst at Wells Fargo Securities, specializing in the oil and gas exploration and production sector with a focus on North American energy companies. He provides coverage on notable firms such as ConocoPhillips, Devon Energy, EOG Resources, Pioneer Natural Resources, and Marathon Oil, earning a reputation for detailed financial analysis and actionable investment insights. Recognized for his strong stock picking abilities, Yennen has achieved a success rate of over 60% on platforms like TipRanks, delivering above-average returns on investment recommendations to clients. Beginning his finance career in the early 2010s, Yennen previously held positions at Tudor, Pickering, Holt & Co. and earned his CFA charter before joining Wells Fargo in 2019.

    Yennen's questions to Kezar Life Sciences (KZR) leadership

    Yennen's questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Yennen of Wells Fargo inquired about the mechanism of action driving UPCR reduction in the MISSION study, the rationale and implications of the amended trial protocol, the definition of a successful response rate, and details regarding the discontinued MARINA trial's enrollment and screen failures.

    Answer

    Chief Scientific Officer Christopher Kirk detailed the broad immunomodulatory mechanism, including reductions in autoantibodies and inflammatory gene signatures. Chief Medical Officer Noreen Henig explained the amended MISSION protocol reflects real-world practice, aiming for a broad label, and noted KZR-616's superior profile for chronic use compared to VELCADE. She also confirmed zero patients were enrolled in the MARINA study.

    Ask Fintool Equity Research AI